Literature DB >> 11123138

Bilateral diaphragmatic paralysis after cardiac surgery: ventilatory assistance by nasal mask continuous positive airway pressure.

B Hoch1, A Zschocke, H Barth, A Leonhardt.   

Abstract

The case of an 8-month-old boy with bilateral diaphragmatic paralysis after surgical reoperation for congenital heart disease is presented. In order to avoid repeated intubation and long-term mechanical ventilation or tracheotomy, we used nasal mask continuous positive airway pressure (CPAP) as an alternative method for assisted ventilation. Within 24 hours the boy accepted the nasal mask and symptoms such as dyspnea and sweating disappeared. Respiratory movements became regular and oxygen saturation increased. Nasal mask CPAP may serve as an alternative treatment of bilateral diaphragmatic paralysis in infants, thereby avoiding tracheotomy or long-term mechanical ventilation.

Entities:  

Mesh:

Year:  2001        PMID: 11123138     DOI: 10.1007/s002460010162

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  4 in total

Review 1.  C 3, 4 and 5, keep the diaphragm alive.

Authors:  Robert I Ross Russell
Journal:  Intensive Care Med       Date:  2006-06-02       Impact factor: 17.440

2.  Bilateral Diaphragmatic Paralysis Following Paediatric Cardiac Surgery: Experience of four cases at the Royal Hospital, Muscat, Oman.

Authors:  Said A M Al-Hanshi; Mohammed H R Al-Ghafri
Journal:  Sultan Qaboos Univ Med J       Date:  2017-10-10

3.  Bilateral diaphragm paralysis following cardiac surgery in children: 10-years' experience.

Authors:  Ovadia Dagan; Revital Nimri; Yakov Katz; Einat Birk; Bernardo Vidne
Journal:  Intensive Care Med       Date:  2006-06-02       Impact factor: 17.440

4.  Electrophysiological evaluation of phrenic nerve injury during cardiac surgery--a prospective, controlled, clinical study.

Authors:  Suat Canbaz; Nilda Turgut; Umit Halici; Kemal Balci; Turan Ege; Enver Duran
Journal:  BMC Surg       Date:  2004-01-14       Impact factor: 2.102

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.